Clinical trial · Interventional
The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device
NCT03006055CI-TRIAL-00025312unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved. Application data of CellCollector in China is not available now. The purpose of this clinical trial is to confirm the validation and safety of CellCollector in Chinese patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cells.Breast | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating tumor cells | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MBC Group
- description
- metastatic breast cancer Age：18-75 ECOG:0-2
- interventionNames
- Device: Circulating tumor cells
- type
- EXPERIMENTAL
- label
- Control Group
- description
- benign breast tumour Age：18-75 ECOG:0-2
- interventionNames
- Device: Circulating tumor cells
Primary outcomes (2)
- measure
- Validation of CellCollector
- timeFrame
- 6 month
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Metastasis breast cancer confirmed with imaging examination * Have agreed to undergo CTC analysis in vivo; * ECOG：0-2 Exclusion Criteria: * Non-metastasis breast cancer
References
Publications (0)
Data not yet available
No reference posted for this study.